Drugs / H3.3-K27M-targeting neoantigen peptides
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04749641 | Mar 2021 → Oct 2024 | diffuse intrinsic pontine glioma | Yang Zhang | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H3.3-K27M-targeting neoantigen peptides | “The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they...” NCT04749641 ↗ |
| Action | Deplete | “APCs can present the peptide with the major histocompatibility complex (MHC) molecules on cell surface, thereby activating neoantigen-specific T cells and triggering...” NCT04749641 ↗ |
| Modality | Peptide | “The researched vaccine is a cancer-treatment vaccine containing an H3.3-K27M targeted neoantigen peptide” NCT04749641 ↗ |